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632 The Journal of Thoracic and CardioObjective: Airway bypass via transbronchial fenestration has been shown to im-
prove forced expiratory volume and flow in explanted human emphysematous
lungs. The aim of this study was to evaluate the feasibility and safety of in vivo
airway bypass stent placement by using a canine model and to assess the influence
of topical mitomycin C on the prolongation of stent patency.
Methods: With dogs under general anesthesia, suitable segmental and subsegmental
bronchial wall sites were selected by direct visualization with a flexible broncho-
scope. Peribronchial blood vessel injury was avoided by using a Doppler probe.
Transbronchial fenestration was formed with a 22-gauge transbronchial needle, and
the passage was then dilated with a 2.5-mm angioplasty balloon. A balloon expand-
able stainless-steel stent (3 mm long  3 mm wide) with a sleeve of silicone rubber
covering was placed within the fenestration. Animals were bronchoscoped weekly
to assess stent patency. Seventy stents were placed in 12 dogs. Thirty-five served as
controls, and the other 35 received transbronchoscopic topical application of mit-
omycin C once weekly to evaluate the effect on the maintenance of stent patency.
Mitomycin C stents were divided into 4 groups according to the number of
treatments: group A, 1 treatment only; group B, 4 weeks; group C, 7 weeks; and
group D, 9 weeks. Each once-weekly mitomycin C application consisted of 0.2 mL
at a concentration of 1 mg/mL, delivered through a small polyethylene catheter.
Results: Four instances of minor and brief bleeding occurred during stent placement
and resolved without incident. One pneumothorax occurred and was treated by chest
tube placement, without any adverse sequelae. There was no mortality associated
with stent placement. No delayed hemorrhage or pneumothorax occurred. All
control stents were occluded at the 1-week follow-up. The median durations of stent
patency for group A (n  8), group B (n  9), group C (n  10), and group D (n
 8) were 3, 8, 13, and greater than 20 weeks, respectively.
Conclusions: Airway bypass stent placement can be performed safely. In an animal
model, most stents became occluded within 1 week, but topical mitomycin appli-
cation resulted in significant prolongation of patency.
The ability of gas to move from one part of the lung to another throughnonanatomic pathways is termed collateral ventilation and was firstobserved by Van Allen and colleagues1 in 1930. The importance ofcollateral ventilation is minimal in normal lungs because the resis-tance to air flow is higher in collateral channels than in the airway.2The resistance of air flow in collateral channels is, however, low in
patients with emphysema in comparison to that in healthy lungs.2,3 In emphysema-
tous lungs, collateral ventilation provides important channels for gas distribution
and may be therapeutically useful.4 Lausberg and colleagues5 have demonstrated
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TSthat the creation of direct passages between emphysematous
pulmonary parenchyma and bronchial airways (airway by-
pass) could take advantage of the extensive collateral ven-
tilation present in emphysema to provide improvement in
expiratory flow and volume, which is otherwise limited by
the collapse of small peripheral airways during expiration.
They reported an ex vivo study on 12 human emphysema-
tous lungs and demonstrated improvement in forced expi-
ratory volume in 1 second from an average of 245 mL at
baseline to an average of 447 mL after the creation of 3
passages and to an average of 666 mL after the creation of
5 airway bypass passages.
These experimental results are promising and warrant
Figure 1. Equipment used in the procedure for airway bypass
stent placement. From top to bottom: 4.9-mm flexible broncho-
scope, Doppler probe, 22-gauge transbronchial cytology needle,
2.5-mm angioplasty balloon, stent mounted on delivery device,
expanded 3-mm  3-mm stent seen front on, and expanded
balloon of the stent-delivery device.further research to evaluate the feasibility and safety of the
The Journal of Thoraciairway bypass procedure in an in vivo setting. Preliminary
experimental study in healthy dogs has shown that airway
bypass stents occluded within a week after placement and
this would pose a major problem for future potential clinical
application. The topical application of mitomycin C, an
anti-inflammatory and antifibrotic agent, has been reported
to be useful in the treatment of airway stenosis.6,7 The
compound selectively inhibits DNA synthesis through mi-
tomycin C–induced cross-linking, and this primarily occurs
at guanine and cytosine. At sufficient drug concentrations,
RNA and protein synthesis are also suppressed.7 These
properties led to its use as an agent for reducing scar
formation. This experimental study was undertaken to eval-
uate the feasibility and safety of airway bypass stent place-
ment by using a canine model and to assess the influence of
topical mitomycin C on stent patency.
Methods
Specially bred research mongrel dogs were used for the experi-
ment. The dogs weighed 20 to 25 kg. The airway bypass procedure
was performed with dogs under general anesthesia, and they were
mechanically ventilated via a single-lumen endotracheal tube. The
equipment used is shown in Figure 1. A standard 4.9-mm external
diameter flexible fiberoptic bronchoscope with a 2-mm working
channel (BF-P160; Olympus American Inc, Melville, NY) was
used to visualize the airway and to select appropriate target sites at
the segmental or subsegmental bronchial level. A Doppler catheter
(Broncus Technologies Inc, Mountain View, Calif) inserted
through the bronchoscope channel was used to scan the target site
and its adjacent area to detect and avoid peribronchial vessels
before transbronchial fenestration. Once the appropriate site was
identified, the Doppler probe was exchanged for a 22-gauge trans-
bronchial needle (WANG transbronchial aspiration needle;
CONMED Corporation, Utica, NY), and the needle was advanced




A Topical application at the time of
placement only
8
B Application at the time of placement and
once weekly for the next 3
consecutive weeks (4 separate
applications)
9
C Application at the time of placement and
once weekly for the next 6
consecutive weeks (7 separate
applications)
10
D Application at the time of placement and
once weekly for the next 8
consecutive weeks (9 separate
applications)
8
*Each weekly topical application was 0.2 mL of 1 mg/mL mitomycin C.through the bronchial wall to create a small passage into the lung
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was slowly withdrawn out of the bronchial wall. The transbron-
chial needle had transparent tubing connected to it that provided
visualization of the aspirated content. The target site was not used
if blood was aspirated or if there was evidence of blood oozing out
from the small hole created after the needle was withdrawn. An
angioplasty catheter with an expandable balloon diameter of 2.5
mm and a length of 30 mm (Cordis Charger PTCA dilatation
catheter; Cordis Corporation, Miami, Fla) was then inserted into
the transbronchial fenestration and dilated to 2.5 mm. A 3-mm–
long  3-mm–wide balloon expandable stainless-steel stent cov-
ered with a sleeve of silicone rubber (Exhale stent; Broncus
Technologies Inc., Mountain View, Calif) was then placed into the
dilated transbronchial passage. The stent expands out on either end
from its mid portion (3 mm wide) to a 5.5-mm flange, which helps
to secure the stent (Figure 1). Control stents received 0.2 mL of
topical normal saline at the time of placement via a delivery
catheter passed through the working channel of the bronchoscope.
Mitomycin C stents received a once-weekly topical application of
0.2 mL of mitomycin C (concentration 1 mg/mL) delivered
through the bronchoscope with the use of a delivery catheter.
Seventy stents were placed in the airways of 12 dogs. Thirty-five
stents acted as controls, and the other 35 stents were treated with
topical mitomycin C. The number of weekly mitomycin C treat-
ments for each stent was determined by the protocol outlined in
Table 1. All 12 dogs had control stents to allow for comparison of
the mitomycin C–treated stents with the control stents in the same
dog. The dogs were bronchoscoped weekly to assess stent
patency and to allow for topical application of mitomycin C.
The stent was defined as occluded if there was tissue ingrowth
to completely fill the inside channel of the stent for at least half
of its length. The general health status of the dog was assessed
TABLE 2. Summary of stent patency
Week Control Group A Group B Group C Group D
1 0/35 8/8 9/9 10/10 8/8
2 8/8 9/9 10/10 7/8
3 3/8 8/9 9/10 7/8
4 1/8 8/9 8/10 6/8
5 1/8 8/9 7/10 6/8
6 1/8 5/9 7/10 6/8
7 1/8 5/9 7/10 6/8
8 1/8 4/9 7/10 6/8
9 1/8 4/9 7/10 6/8
10 1/8 4/9 7/10 6/8
11 1/8 3/9 7/10 6/8
12 1/8 3/9 6/10 6/8
13 1/8 2/9 4/10 6/8
14 1/8 2/9 4/10 5/8
15 1/8 2/9 3/10 5/8
16 1/8 2/9 3/10 5/8
17 1/8 2/9 3/10 5/8
18 1/8 2/9 3/10 5/8
19 1/8 2/9 3/10 5/8
20 1/8 2/9 3/10 5/8by daily clinical examination and weekly complete blood count,
634 The Journal of Thoracic and Cardiovascular Surgery ● Marurea, and electrolyte laboratory blood tests. Weekly follow-up
was performed up to a maximum of 20 weeks. The study had
obtained animal studies ethics committee approval.
Results
Four episodes of minor and brief bleeding occurred during
stent placement. These were treated with diluted topical
epinephrine solution and resolved without incident. A pneu-
mothorax developed after placement of 1 airway bypass
stent. The stent was removed, and the transbronchial pas-
sage was sealed with a blood patch that clotted within the
passage. The pneumothorax was treated with insertion of a
chest tube, and the dog recovered well without sequelae.
Leukopenia developed in 1 dog with a white blood cell
count of 4.5 U 103 cells/mL (normal range, 6.0-17.0 U
103 cells/mL). The white cell count level returned to a
normal value within 3 days without further recurrence or
clinical illness. There was no early or late mortality related
to the airway bypass stents. No delayed hemorrhage or
pneumothorax occurred. Control stents were all occluded at
the first week of bronchoscopic follow-up. In contrast, mi-
tomycin C–treated stents had a prolongation of stent pa-
tency, and the duration of stent patency was associated with
the number of once-weekly topical mitomycin applications
(Table 2; Figure 2). The median duration of stent patency in
groups A, B, C, and D was 3, 8, 13, and greater than 20
weeks, respectively (Table 2; Figure 2). On the 20th week
of follow-up, 5 of the 8 stents in group D were still patent.
Examples of patent and occluded stents as visualized on
bronchoscopy are shown in Figure 3.
Discussion
Emphysema is a common disease that affects approximately
2 million individuals in the United States and is the fourth
leading cause of death. It is anatomically defined as an
irreversible increase in the size of the air spaces distal to the
terminal bronchioles. This increase results from the destruc-
tive activity of neutrophil and macrophage elastase.8 The
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Figure 2. Kaplan-Meier freedom from stent closure, stratified by
treatment group.loss of lung tissue alters the physical properties of the lung
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dynamic hyperinflation of the lungs. These changes result in
enlargement of the thorax, flattening of the diaphragm,
increased work of breathing, increased dyspnea, and re-
duced exercise tolerance.9 The progressive loss of elastic
recoil traps the patient in a state of hyperinflation in which
forced expiratory effort cannot reduce the residual volume,
because the force extended to empty the lungs collapses the
small airways and obstructs the outflow of gas. Progressive
hyperinflation of the lungs and hyperextension of the chest
Figure 3. Examples of patent and occluded stents visu
B, Occluded control stent at the 1-week follow-up. C, P
mitomycin C stent at the 14-week follow-up.wall also diminishes inspiratory capacity. To maintain ad-
The Journal of Thoraciequate minute ventilation, the respiratory rate must increase,
resulting in an increase in the work of breathing and in
dyspnea.10
Surgical options in the treatment of emphysema include
lung transplantation and lung volume reduction surgery.
Both of these treatment modalities have specific indications,
and their use is limited to selected patients. Our group
embarked on an experimental study of airway bypass with
the goal of developing a palliative treatment for patients
with homogenous severe emphysema who are not candi-
d on bronchoscopy. A, Stent at the time of placement.
t mitomycin C stent at the 1-week follow-up. D, Patentalize
atendates for either lung transplantation or lung volume reduc-
c and Cardiovascular Surgery ● Volume 129, Number 3 635
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the creation of extra-anatomic bronchopulmonary passages
in ex vivo emphysematous lungs resulted in the improve-
ment of forced expiratory flow and volume.5 The transbron-
chial passages created took advantage of the extensive col-
lateral ventilation present in emphysematous lungs to allow
for additional removal of trapped gas and further reduction
of residual volume not obtainable through the airways. The
airway bypass stent was developed as a noncollapsing struc-
ture to prevent the collapse and closure of the transbronchial
passages. Crucial steps in the clinical performance of this
procedure include the ability to safely place airway bypass
stents transbronchially without any associated early or late
morbidity. Maintenance of stent patency is also an impor-
tant factor if the treatment is to become clinically useful,
with potential durable benefits. Our experiment was de-
signed to address these issues.
Our earlier experimental work used a radiofrequency
device to create the transbronchial passage.5,11 This device,
however, has the potential disadvantages of injuring adja-
cent tissues because of the radial spread of heat and of
penetrating too deeply, with resultant hemorrhage or pneu-
mothorax. The 22-gauge cytology needle was chosen in this
experiment because it had the advantage of creating only a
tiny transbronchial passage. Any bleeding encountered from
the puncturing of a peribronchial blood vessel would be
expected to be self-limited. The ability to judge the distance
and control the advancement of the needle and the ability to
aspirate through the needle were thought to be additional
safety features of using a needle to initially form a small
transbronchial track. With this technique, we did not en-
counter any major hemorrhage in the placement of 70 stents
in 12 dogs. All 4 episodes of bleeding were minor and brief.
They were treated with diluted topical epinephrine solution
and resolved without incident. The balloon was used to
enlarge the small transbronchial passage to allow for the
placement of the stent-delivery device within the passage.
The balloon was thought to provide an additional benefit in
that if bleeding occurred after dilation of the tract, it could
potentially be used to tamponade the bleeding. By compar-
ison, the radiofrequency device did not have the safety
features of the needle-and-balloon technique as described
here. The needle-and-balloon technique, however, is asso-
ciated with the disadvantages of requiring 2 separate de-
vices and procedural steps, which could result in added
complexity and prolonged time to form the transbronchial
passage. In our opinion, the potential safety features of the
needle-and-balloon technique outweigh those of the radio-
frequency device, and the study was performed with the
needle-and-balloon technique to evaluate the feasibility and
safety of such a technique. A combined needle-and-balloon
device has subsequently been developed to overcome the
636 The Journal of Thoracic and Cardiovascular Surgery ● Mardisadvantages encountered with the separate needle and
balloon devices used in this study.
Mitomycin C is known to inhibit fibroblast proliferation
and vascular ingrowth in tissues, and these properties have
led to its topical use in clinical ophthalmologic surgery. In
1963, Kunitomo and colleagues12 first introduced the topi-
cal use of mitomycin C in the eye after pterygium surgery.
Chen13 in 1983 reported the use of mitomycin C as adjunc-
tive therapy in trabeculectomy surgery for glaucoma. The
authors found that it reduced scarring at the scleral flap with
100% success at the relatively low dose of 0.02%. A dou-
ble-blinded, prospective study in 1988 helped to popularize
its use in North America by showing a decrease in the
pterygium recurrence rate from 88.9% to 2.3% when com-
pared with placebo.14 The use of topical mitomycin C on
respiratory epithelium, specifically on nasal mucosa, was
first explored as adjunctive therapy in dacryocystorhinosto-
my.15 A recent study by Ingram and colleagues16 found it to
be effective in maintaining patent maxillary antrostomy
sites in a rabbit model. Electron microscopy revealed that
after an initial period of ciliary loss, no permanent damage
to the mucosa was noted, and there was a return of normal
ciliary function within 1 week. Topical mitomycin C has
also been reported to inhibit the formation of granulation
tissue in the airway and has been found to be useful in the
treatment of difficult airway stenosis.6 Its usefulness in the
prevention and reduction of laryngotracheal stenosis has
been shown in several animal studies.17-19 Successful clin-
ical application of topical mitomycin C for the treatment of
glottic and subglottic stenosis has also been reported in the
otorhinolaryngology literature.20,21 On the basis of these
findings, we chose to assess the effects of topical mitomycin
C on airway bypass stent patency. Our results suggest that
stent patency may be prolonged with a single topical appli-
cation of mitomycin C and that the duration of stent patency
was further prolonged in association with an increase in the
number of once-weekly treatments.
The more frequently used dosage of mitomycin C as a
chemotherapeutic agent is 10 to 20 mg/m2 of body-surface
area and is given as a single-bolus intravenous injection.
This treatment is repeated on a cycle of every 6 to 8 weeks.
For a person with a body weight of 70 kg and surface area
of 2.16 m2, a single injection of 21.6 and 43.2 mg would
correspond to a dosage of 10 and 20 mg/m2, respectively.
Our study used only a small amount of topical mitomycin C
relative to the systemic chemotherapeutic dose delivered to
oncology patients. Only approximately 0.6 mg would have
been delivered topically in the treatment of 3 stents per
week. In our study, we did not observe any significant local
adverse effects. A transient episode of leukopenia, however,
did develop in 1 dog and it is possible that systemic absorp-
tion had occurred, with resultant mitomycin C toxicity and
bone marrow suppression. This is certainly a possible side
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mitomycin C and monitoring of the serum level are impor-
tant issues that require further future evaluation and this is
a limitation of this study. Titration to dose-response levels
and assessment of toxicity need to be performed before
application in humans. However, this study was primarily
designed to find out whether stent patency could be pro-
longed by local application of an antifibrotic agent. The
affirmative results suggest that a drug-eluting stent may well
be worth developing. This would have the advantage of
avoiding the weekly treatment schedules, which would be
impractical in the clinical setting.
In summary, it was feasible and safe to perform airway
bypass stent placement in vivo. In the canine model, the
control stents became occluded within 1 week. Topical
mitomycin C application, however, resulted in a prolonged
duration of stent patency, and the duration of stent patency
was associated with the duration of mitomycin C treatment.
The results confirm that the wound-healing process in re-
sponse to the airway bypass stent can be suppressed by
topical application of anti-inflammatory or antifibrotic
agents.
We thank Patricia Toeniskoetter, Naomi Still, and Katheryn
Cook for their technical assistance.
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Discussion
Dr Scott J. Swanson (New York, NY). Your paper is quite inter-
esting. Do you know where the distal end of your stent sits? Have
you ever done bronchography or a computed tomographic scan to
look at this?
Dr Choong. The stents go through the transbronchial wall into
the lung parenchyma, and because we’re using normal research
dogs, the passage creation goes straight into solid lung paren-
chyma. We have, however, tried this on explanted transplant
recipient emphysematous lungs, as well as in patients before either
lobectomy or pneumonectomy, and we have observed that the
transbronchial passage goes straight into emphysematous lung. We
have a video clip if you would like to have a quick look for this
discussion that demonstrates the passage into human emphysema-
tous lungs.
Dr Swanson. Do you have any plans for human trials with this?
Dr Choong. In the future we do. This is, however, only a
preliminary study just to assess the effects of topical mitomycin.
Obviously, weekly application of topical mitomycin is not practi-
cal. Therefore, the principle behind this study was to evaluate
whether it was feasible and safe to use topical mitomycin and then
subsequently to consider developing a drug-eluting stent for con-
sideration in human application.
Dr Sudish Murthy (Cleveland, Ohio). Congratulations, Cliff.
It’s a very provocative study. We have been relatively disap-
pointed with the use of topical mitomycin to maintain larger
airway stent patency. I’m just wondering if the passage of that
delivery catheter once a week is enough to dilate these stents and
maintain patency. It looked like you were inserting the delivery
catheter through the stent, and I’m just wondering if this isn’t an
epiphenomenon of the mitomycin instillation, since that wasn’t
done in control cases.
Dr Choong. The catheter was just used to deliver the topical
mitomycin. We do not place the catheter through the stent into the
passage or the lung itself.
Dr Walter Weder (Zurich, Switzerland). Have you seen local
necrosis or other local toxicity in the repeated group?
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effects from the topical mitomycin. I think that may be most likely
due to the low concentration and low dose that we’re using.
Dr Thomas M. Egan (Chapel Hill, NC). That was a very
nicely presented piece of work and very interesting. Your group
has some experience with emphysematous dogs, as I recall. Are
the patency rates of these stents any better in dogs with emphy-
sema?
638 The Journal of Thoracic and Cardiovascular Surgery ● MarDr Choong. We have not used these stents in any of the
emphysematous dogs.
Dr Egan. The next question is—and your data beg the ques-
tion—have you any experience with drug-eluting stents, such as
rapamycin-eluting stents?
Dr Choong. We have looked into that previously just as a
preliminary evaluation, and the results have not been as good as
using repeated weekly topical mitomycin.
ch 2005
